U.S. FDA grants accelerated approval to HERNEXEOS® for previously treated patients with HER2-mutant advanced NSCLC August 12, 2025
First patient dosed in pivotal Ph 3 AK112-305/HARMONi-8A trial of ivonescimab + docetaxel for PD-1/L1i & chemo-refractory NSCLC August 5, 2025
Targeted Enrollment Completed for Lung Cancer Ph 2 Harmonic™ Trial in Japan for LP-300 August 5, 2025
Preliminary Safety & Efficacy Data Announced from Trial of IMM2510/AXN-2510 in Combination with Chemo in 1L NSCLC in China August 5, 2025
NMPA accepts NDA for sevabertinib (BAY 2927088) for previously treated NSCLC patients with HER2/ERBB2 mutations July 29, 2025
FDA Breakthrough Therapy Designation for Elironrasib for KRAS G12C-mutated locally advanced or metastatic NSCLC July 29, 2025
ALKAZAR Ph 3 Trial of Neladalkib for Patients with TKI-naïve ALK-positive NSCLC initiated July 23, 2025
Tagrisso + chemo demonstrated statistically significant and clinically meaningful improvement in OS in EGFR-mutated advanced lung cancer July 23, 2025
ZEGFROVY (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for NSCLC with EGFR Ex 20 Insertion Mutations July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
Positive pivotal data announced for zidesamtinib in TKI pre-treated patients with ROS1-positive NSCLC from ARROS-1 Ph 1/2 trial July 1, 2025
First patient dosed in Ph 1/2 trial of TNG462 and daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer July 1, 2025
NMPA approves ORPATHYS + TAGRISSO combo in China for the Treatment of Lung Cancer Patients with MET Amplification After Progression on 1L EGFR Inhibitor July 1, 2025
Positive Interim Firmonertinib Monotherapy Data Announced From Global Ph 1b Study in EGFR PACC Mutant NSCLC; Plans to Advance into a Global Pivotal Study June 24, 2025
